Asthma Treatment Market Size & Trends:

The Asthma Treatment Market size was valued at USD 26.78 billion in 2024 and is expected to reach USD 36.36 billion by 2032, growing at a CAGR of 3.99% over the forecast period of 2025-2032.

The global asthma treatment market is growing due to the growing prevalence of asthma, higher adoption of biologics for severe cases, and advances in inhaler technology. Increase in positive reimbursement policies, rising awareness, and enhanced diagnosis are other factors driving the asthma treatment market growth. Moreover, the rising trend of personalized medicine and home care services has broadened the scope of the market. Due to robust R&D pipelines and product approvals, the market is projected to grow steadily in developed and emerging economies in the forecast period.

To Get more information on Asthma Treatment Market - Request Free Sample Report

The U.S. asthma treatment market size was valued at USD 8.18 billion in 2024 and is expected to reach USD 10.81 billion by 2032, growing at a CAGR of 3.64% over the forecast period of 2025-2032.

The U.S. is the largest contributor to the North American asthma therapeutics market as it has a highly developed healthcare infrastructure, high asthma incidence rates, and well-established use of inhaled therapy and biologics. The market is also supported by robust R&D, as well as a conducive reimbursement landscape.

Asthma Treatment Market Dynamics:

Drivers

• The Market Growth is Being Driven by Advancements in Technology and the Development of Inhaled and Biologic Therapies

Asthma management has been revolutionized by the introduction of new inhalation devices and specific biologics. Novel inhalers, including DPIs and smart inhalers, have been introduced to facilitate accurate drug delivery, using digital means to track adherence and inhalation technique in real-time. Furthermore, combination therapies (inhaled corticosteroids and long-acting bronchodilators) provide better symptom control in one drug delivery system. These advances both optimize the efficacy of treatment and promote patient convenience and compliance, which is essential for the treatment of a chronic disease.

Smart inhalers and linked devices are improving adherence to treatment, monitoring of inhaler technique, and decreasing asthma-related hospital admissions.

These tech tools have proven more effective to help with asthma control, particularly among teens and technology-savvy patients, according to Pulmonology Advisor.

There are companies, such as GSK, working on low-carbon propellant inhalers to achieve environmental goals and lessen carbon footprints.

GSK’s switch to a new propellant in its Ventolin inhalers could cut its carbon footprint by more than 40%.

• Rising Adoption of Biologics for Severe Asthma to Drive the Market Growth

Biologics are changing the approach to severe, uncontrolled asthma in certain phenotypes, such as eosinophilic or allergic asthma. Molecules such as omalizumab (anti-IgE), mepolizumab, and benralizumab (anti-IL-5) offer targeted biologics that modify immune activity through inhibition of inflammation and protection from frequent exacerbations. Unlike traditional treatments, biologics provide their benefits longer and with fewer side effects for patients who don’t respond to inhaled treatments alone. Expanding regulatory approvals, increasing physician comfort, and enhanced insurance coverage are driving the adoption of the devices in developed markets.

Biologics, including mepolizumab, benralizumab, dupilumab, and tezepelumab, have dramatically decreased the rates of asthma exacerbation and hospitalization in severe asthma patients.

ScienceDirect reported those biologics cut the rates of these exacerbations needing hospitalizations or ER visits by about 56% in real-world and clinical trials.

Mepolizumab and omalizumab biosimilars (e.g., Omlyclo) have been approved in key markets such as China, the U.S., and the EU in the recent past.

Springer Nature said this approval extends patient access to precision asthma treatment and contributes to the growth of the biologics market.

Restraint

• The Exorbitant Cost of Advanced Therapies, Particularly Biologics, is Limiting the Market Growth

Biologic agents— including mepolizumab (Nucala), dupilumab (Dupixent), benralizumab (Fasenra), and others — have transformed care for people with tough-to-treat, severe, eosinophilic (or allergic) asthma. But these drugs can run to USD 30,000 – USD 40,000 a year per patient – a cost that puts them out of reach of many, particularly among poorer or underinsured populations.

They are clinically effective with strong evidence from randomized controlled trials, but they are priced high, and access is often restricted to a minority of eligible patients. And directly in developed countries, insurance and reimbursement barriers can be a roadblock to access, delay, or limitations on access. In these economies with high levels of out-of-pocket healthcare costs, access to these therapies is mostly limited, slowing market penetration and treatment coverage in general. This economic barrier highly limits the broader use of biologics in the management of asthma.

Asthma Treatment Market Segmentation Analysis:

By Treatment Type

Long-term control medications segments led the asthma treatment market share in 2024 with a 62.4% owing as these drugs play an important role in controlling persistent asthma and also help avert exacerbations. Inhaled corticosteroids, long-acting beta agonists, leukotriene modifiers, and combined therapies are commonly used as maintenance and for symptom control daily. These agents are included among the first-line agents for global asthma guidelines, particularly in moderate to severe cases. They are widely used and dominant in the market because of their potency to reduce inflammation, reduce the number of asthma attacks, and improve the quality of life.

The biologics segment, comprising omalizumab, mepolizumab, and benralizumab, is expected to be the fastest-growing segment over the forecast period due to the growing targeted therapeutic action and rising demand for uncontrolled, severe asthma. These treatments are tailored for patients with type 2 inflammation and high eosinophils, resulting in significantly greater improvements in symptom control and reductions in hospitalizations. Increasing physician comfort, more widespread regulatory approval, increasing payer coverage, and ongoing R&D investment are some of the factors driving quick adoption of biologics, especially in developed markets.

By Route of Administration

The inhalers segment led the 2024 asthma treatment market share with a 68.5% owing to their efficiency, user-friendliness, and availability for maintenance and rescue therapy across the globe. Inhalation therapy with inhalers such as metered-dose inhalers (MDIs) and dry powder inhalers (DPIs) provides the advantage of targeting drug delivery to the lung for quick symptomatic relief and localized drug action and minimizing systemic side effects. Ease of use and patient preference, together with high physician dependence on inhaled corticosteroids and combination inhalers, have led to this route being the most widely used and available form of treatment in all ages and severities.

Injectable is the fastest-growing segment in the forecast period, owing to the high adoption of biologic therapies among patients with severe and refractory asthma. These injectable medications, which include mepolizumab, benralizumab, and dupilumab, target treatment in phenotypes of asthma, particularly eosinophilic and allergic asthma. With mounting clinical evidence associated with their efficacy and broadening availability of specialty care, the utilization of subcutaneous and intravenous biologics is rapidly rising. Improved self-injection systems and enhanced reimbursement both play a role in the increasing acceptance and choice for injectables by both patients and physicians.

By Medication Type

The controller medications segment held the majority of the share in the asthma treatment market in 2024, with around 39.6% market share, as they are necessary for the prolonged control of asthma and to prevent symptoms from worsening. These drugs, which include inhaled corticosteroids, LABAs, and leukotriene receptor antagonists, are used to control airway inflammation and bronchial hyper-responsiveness daily. Their high level of use in children and adults, driven by clinical guidelines and physician preference, has made controller therapies the mainstay of asthma management from mild to severe.

The preventive medications market segment is projected to be the fastest-growing segment in the global market over the forecast years, influenced by a global trend toward early and proactive management of asthma. Rising awareness of the asthma triggers, advances in diagnosis, and the focus on preventing disease progression are promoting the use of preventive treatments, especially in those at high risk, including children and those with allergic asthma. Furthermore, the increasing number of biologics and immunomodulators in the pipeline for prevention purposes, at a rate where personalized treatment option tends to be in the limelight, the sector is progressing extraordinarily in this segment as well.

By Age Group

The adult segment held the major market share of the asthma treatment market in 2024, with a 46.3% due to the increasing number of patients diagnosed with asthma, easy access to healthcare, and continuous treatment regimen among adults. Adults are more likely to opt for medical aids, long-term medications, and a combination of controllers and rescue medications, which is boosting the market consumption. Furthermore, adult-onset asthma, which is frequently more severe and persistent, also demands long-term control measures as well as greater usage of emerging treatments such as biologics or combination inhalers, which will continue to strengthen the segment’s dominance.

The pediatric segment is anticipated to observe the fastest growth during the forecast period, owing to the increasing prevalence of childhood asthma across the world (especially in urban and polluted areas). Greater emphasis on early diagnosis, school-based asthma management programs, and availability of age-appropriate formulations and devices (e.g., pediatric-friendly inhalers and nebulizers) is making treatment more accessible. Also, increased awareness of parents and health professionals about the long-term effects of uncontrolled asthma in children is fueling the demand for preventive and controller medication in the preschool and school-age patient population.

Asthma Treatment Market Regional Insights:

North America holds a leading position in the asthma treatment market trend with a 40.1% market share in 2024, on account of the presence of developed healthcare infrastructure, high disease awareness, and accessibility of advanced treatment options- biologics, combination inhalers, and digital therapeutics. Strong regulatory support, high healthcare expenditure, and reimbursement policies that enable access to both branded and novel agents benefit the region. North America continues to lead in terms of advances in asthma care due to the existence of major pharmaceutical players in the region, continued clinical studies, and initial acceptance of novel drug delivery systems.

The Asia Pacific region is the fastest-growing in the asthma treatment market analysis due to rising prevalence of asthma, increasing pollution levels, and rapid urbanisation. Growing access to health care, increased patient awareness, and increased insurance coverage in nations such as China, India, and Southeast Asia are the factors contributing to the growing demand for asthma drugs and devices. Furthermore, the increase in the size of the middle class, along with government efforts to improve respiratory disease management, and increased investments from multinational pharma companies in local markets, are creating opportunities for market expansion in the region.

Rising patient pull for effective drugs and increasing prevalence of asthmatic population have made Europe an emerging region in the asthma treatment market with strong medical support, vast knowledge in asthma control programmes, and higher treatment facilities. Growth is driven by countries such as Germany, the UK, and France, which have embraced the use of biologics and combination inhalers in addition to launching national asthma treatment programs. Strong reimbursement guidelines and a steady adherence to clinical guidelines facilitate access to novel treatments, and as such, Europe is a strong and growing market for asthma management.

The asthma treatment market analysis in Latin America is growing at a moderate rate, due to an increase in the prevalence of asthma, improved public healthcare, and an awareness level of respiratory diseases. The countries gradually started adopting controller and reliever therapies along with increased accessibility to inhalation-based therapies. Government funding and measures to improve primary healthcare facilities are improving the rate of diagnosis and treatment in the region.

MEA asthma treatment market is also growing at a stable pace due to increasing healthcare facilities and rising concern for chronic respiratory diseases in the region. National initiatives to improve asthma care and access to appropriate medications and combination therapies are being set up in countries such as Saudi Arabia, the United Arab Emirates (UAE), and South Africa.

Get Customized Report as per Your Business Requirement - Enquiry Now

Key Players in the Asthma Treatment Market:

The asthma treatment market companies are GlaxoSmithKline plc (GSK), AstraZeneca plc, Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Merck & Co., Inc., Roche Holding AG, Cipla Ltd., Mylan N.V. (Viatris Inc.), Regeneron Pharmaceuticals, Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Orion Corporation, Zambon S.p.A., Vectura Group plc, Mundipharma International Limited, Glenmark Pharmaceuticals Ltd., Amgen Inc., and other players.

Recent Developments in the Asthma Treatment Market:

• May 2024 – GSK plc released positive topline results from its Phase III clinical trials, SWIFT-1 and SWIFT-2, assessing the efficacy and safety of depemokimab versus placebo in adults and adolescents with severe asthma with type 2 inflammation, defined by high blood eosinophil counts. Both trials met their primary objectives by confirming a substantial decrease in the annualized rate of clinically significant asthma exacerbations over 52 weeks.

• May 2024 – AstraZeneca highlighted new clinical and real-world evidence from its broad respiratory portfolio during the American Thoracic Society (ATS) International Conference in San Diego, California. The company featured 59 abstracts, of which 12 were late-breaking posters, highlighting major unmet needs in chronic obstructive pulmonary disease (COPD), severe asthma, and eosinophilic granulomatosis with polyangiitis (EGPA), as well as other chronic respiratory diseases.

  Asthma Treatment Market Report Scope:

  Report Attributes	Details
  Market Size in 2024	USD 26.78 Billion
  Market Size by 2032	USD 36.36 Billion
  CAGR	CAGR of 3.99% From 2025 to 2032
  Base Year	2024
  Forecast Period	2025-2032
  Historical Data	2021-2023
  Report Scope & Coverage	Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
  Key Segments	• By Treatment Type (Long-Term Control Medications, Quick-Relief Medications (Rescue Medications), Others) • By Route of Administration (Inhalers, Nebulizers, Oral, Injectable) • By Medication Type (Controller Medications, Reliever Medications, Preventive Medications) • By Age Group (Pediatric, Adult, Geriatric) • By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) • By End User (Hospitals & Clinics, Homecare, Specialty Centers)
  Regional Analysis/Coverage	North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
  Company Profiles	The asthma treatment market companies are GlaxoSmithKline plc (GSK), AstraZeneca plc, Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Merck & Co., Inc., Roche Holding AG, Cipla Ltd., Mylan N.V. (Viatris Inc.), Regeneron Pharmaceuticals, Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Orion Corporation, Zambon S.p.A., Vectura Group plc, Mundipharma International Limited, Glenmark Pharmaceuticals Ltd., Amgen Inc., and other players.